Ultragenyx Pharmaceutical (RARE) Change in Accured Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Change in Accured Expenses data on file, last reported at -$57.0 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 18.75% year-over-year to -$57.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 million (down 56.57% YoY) and the FY2025 annual result came in at $24.0 million, down 48.94% from the prior year.
• Change in Accured Expenses declined to -$57.0 million in Q1 2026 per RARE's latest filing, from $37.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $57.4 million in Q2 2022 and bottomed at -$57.0 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $11.2 million (2022), against an average of $5.5 million.
• The widest annual swing landed in 2022, when Change in Accured Expenses jumped 375.52%; it then sank 140.02% in 2025.
• Tracing RARE's Change in Accured Expenses over 5 years: stood at $27.4 million in 2022, then plunged by 44.49% to $15.2 million in 2023, then jumped by 204.72% to $46.4 million in 2024, then dropped by 20.22% to $37.0 million in 2025, then tumbled by 254.0% to -$57.0 million in 2026.
• Per Business Quant, the three latest RARE Change in Accured Expenses figures stand at -$57.0 million (Q1 2026), $37.0 million (Q4 2025), and $45.1 million (Q3 2025).

Peer Comparison